Author(s): Ernest Nadal, MD, PhD1,2; Delvys Rodríguez-Abreu, MD3; Marta Simó, MD, PhD4; Bartomeu Massutí, MD, PhD5; Oscar Juan, MD, PhD6; Gerardo Huidobro, MD7; Rafael López, MD8; Javier De Castro, MD, PhD9; Anna Estival, MD, PhD10; Joaquín Mosquera, MD11; Ivana Sullivan, MD, PhD12; Enriqueta Felip, MD, PhD13; Ana Blasco, MD14; Maria Guirado, MD15; Eva Pereira, BoS16; Noelia Vilariño, MD1,2,4; Valentín Navarro, PhD1; and Jordi Bruna, MD, PhD4
Author Affiliations
1Department of Medical Oncology, Institut Català d’Oncologia (ICO), L’Hospitalet de Llobregat, Barcelona, Spain; 2Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain; 3Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; 4Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO, IDIBELL, L’Hospitalet, Barcelona, Spain; 5Department of Medical Oncology, Hospital General de Alicante, Alicante, Spain; 6Department of Medical Oncology, Hospital Universitari La Fe, Valencia, Spain; 7Department of Medical Oncology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain; 8Department of Medical Oncology, Hospital Clínico de Valladolid, Valladolid, Spain; 9Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain; 10Department of Medical Oncology, Institut Català d’Oncologia (ICO), Badalona, Spain; 11Department of Medical Oncology, Hospital Universitario A Coruña, A Coruña, Spain; 12Department of Medical Oncology, Hospital Sant Pau, Barcelona, Spain; 13Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain; 14Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain; 15Department of Medical Oncology, Hospital Universitario de Elche, Elche, Spain; 16Spanish Lung Cancer Group, Barcelona, Spain